Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953726 · ClinicalTrials.gov registry record · Phase 4
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
A Phase 4 study, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10,000
- Enrollment target
NCT06953726: Recruiting Phase 4 study, sponsored by VA Office of Research and Development.
NCT06953726 is a Phase 4 study that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 10,000 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1834% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06953726, a Phase 4 study, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10,000 participants
- Enrollment target
Study Summary
* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban. * The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.
Primary Outcome
Hospitalization for first ISTH-defined major bleeding, as determined by ICD-10 codes associated with hospitalization. This is the primary safety outcome.
Interventions
- DRUG Apixaban
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2033-10-03 |
| Phase | Phase 4 |
What NCT06953726 shows while recruiting
NCT06953726 is an interventional study that assigns participants to a tested intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1834% higher).
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT06953726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06953726 about?
NCT06953726 is a clinical study titled "Comparing the Safety and Efficacy of Apixaban and Rivaroxaban". * The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They ar...
What is the current status of trial NCT06953726?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10,000 participants. The study started on 2026-06-01. Estimated completion is 2033-10-03.
What interventions are being tested in trial NCT06953726?
The interventions under investigation include: Apixaban (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT06953726?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06953726's enrollment target sits among peer trials
10,000 9th of 2000 higher than 1,992 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI